BridgeMD
Study comparing two dosing methods of tocilizumab in patients with rheumatoid arthritis in remission or with low disease activity
EU CTIS ID: 2025-522319-41-00
What this study is testing
The non-inferiority of TOCILIZUMAB in dose-banding will be evaluated through the study of the changes in the DAS28 activity score. The change in this activity score between M0 and M3 will be calculated
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age > 18 years
- Diagnosis of rheumatoid arthritis according to ACR/EULAR criteria
- Rheumatoid arthritis with low disease activity or remission according to DAS28 ...
- Patient to receive a TOCILIZUMAB infusion at 8 mg/kg
- Patient failing treatment with cDMARDs or bDMARDs
- Allowed concomitant treatment(s) for rheumatism: stable doses for at least 3 months of cDMARDs, NSAIDs, analgesics, or corticosteroids (< 10 mg/day of prednisone equivalent)
You likely can't join if
- Active neoplasm
- Treatment with TOCILIZUMAB for an indication other than rheumatoid arthritis
- Treatment with TOCILIZUMAB at a dosage other than 8 mg/kg
- Diverticulitis or history of digestive perforation
- Ongoing pregnancy. A blood pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a doctor of her choice.
- Active hepatitis B
See the full eligibility criteria
- Age > 18 years
- Diagnosis of rheumatoid arthritis according to ACR/EULAR criteria
- Rheumatoid arthritis with low disease activity or remission according to DAS28 ...
- Patient to receive a TOCILIZUMAB infusion at 8 mg/kg
- Patient failing treatment with cDMARDs or bDMARDs
- Allowed concomitant treatment(s) for rheumatism: stable doses for at least 3 months of cDMARDs, NSAIDs, analgesics, or corticosteroids (< 10 mg/day of prednisone equivalent)
- Signing of the informed consent
- Affiliation to a social security scheme
- Active neoplasm
- Treatment with TOCILIZUMAB for an indication other than rheumatoid arthritis
- Treatment with TOCILIZUMAB at a dosage other than 8 mg/kg
- Diverticulitis or history of digestive perforation
- Ongoing pregnancy. A blood pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a doctor of her choice.
- Active hepatitis B
- Untreated latent tuberculosis
- Severe or active infection (except for COVID-19)
- Vulnerable individuals: minors, adults under guardianship or curatorship
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.